Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

Down syndrome, which causes a range of developmental differences and affects 1 in 700 newborns in the United States, is caused by the presence of an extra copy of chromosome 21. Mongkolchon ...

CAMBRIDGE, MA, USA I June 18, 2025 I Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and ...

Biogen has commenced dosing in the Phase III BRAVE study to assess omaveloxolone in children of two to less than 16 years of age with Friedreich ataxia (FA). The trial aims to assess the safety ...

In the study, researchers found that the brains of people diagnosed with Down syndrome and Alzheimer's disease (DSAD) had twice as much iron and more signs of oxidative damage in cell membranes ...

Biogen has commenced dosing in the Phase III BRAVE study to assess omaveloxolone in children of two to less than 16 years of age with Friedreich ataxia (FA). The trial aims to assess the safety, ...

Biogen has initiated the BRAVE study, a global Phase 3 clinical trial to evaluate omaveloxolone in children with Friedreich ataxia, addressing a critical unmet need in the pediatric population.

Company News Published 06/18/2025, 07:35 AM 0 Biogen initiates phase 3 trial of omaveloxolone for children with FA BIIB -0.66% ...

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the ...

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the ...

According to Benzinga Pro, Biogen's peer group average for short interest as a percentage of float is 6.94%, which means the company has less short interest than most of its peers.